Pharma firm Glenmark on Monday said it had settled all pending patent disputes with U.S.-based Medicis Pharmaceutical Corp over a skin disease drug, besides signing a licensing agreement for new drug delivery system (NDDS).
The company through its U.S.-based subsidiary Glenmark Generics has announced the settlement of all litigation pending between Medicis and Glenmark related to the generic version of Vanos and Loprox gel, used in the treatment in dermatology therapeutic area, Glenmark spokesperson told PTI.
This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every
month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
You have read {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.